Difference between revisions of "Tendering process for pneumococcal conjugate vaccine"
From Testiwiki
m |
m |
||
| Line 8: | Line 8: | ||
== Scope == | == Scope == | ||
* We restrict the analysis to vaccination within the infant immunisation programme. | * We restrict the analysis to vaccination within the infant immunisation programme. | ||
| − | * We specify criteria for comparing pneumococcal conjugate vaccine products (in Finnish: [[Vertailuperusteet|Vertailuperusteet]]). | + | * We specify criteria for comparing pneumococcal conjugate vaccine products (in Finnish: [[:op_fi:Vertailuperusteet|Vertailuperusteet]]). |
* The aim is to prepare selection criteria that lead to choice of the economically most advantageous tender. | * The aim is to prepare selection criteria that lead to choice of the economically most advantageous tender. | ||
* We discuss assumptions underlying the epidemiological model and the cost-effectiveness analysis. | * We discuss assumptions underlying the epidemiological model and the cost-effectiveness analysis. | ||
| Line 21: | Line 21: | ||
The rationale has been summarised in the following 3 pages: | The rationale has been summarised in the following 3 pages: | ||
| − | [[Vertailuperusteet|Vertailuperusteet]] (in Finnish), [[Epidemiological_modelling|Epidemiological modelling]] ja [[Taloudellinen_arviointi|Taloudellinen arviointi]] (in Finnish). | + | [[:op_fi:Vertailuperusteet|Vertailuperusteet]] (in Finnish), [[Epidemiological_modelling|Epidemiological modelling]] ja [[:op_fi:Taloudellinen_arviointi|Taloudellinen arviointi]] (in Finnish). |
| − | Comparison of vaccine products will be based on their price and expected health benefits (in Finnish: [[Vertailuperusteet|vertailuperusteet]]). | + | Comparison of vaccine products will be based on their price and expected health benefits (in Finnish: [[:op_fi:Vertailuperusteet|vertailuperusteet]]). |
The health benefits mean the expected reduction in the annual number of invasive pneumococcal disease in the Finnish population, if the vaccine would be used in the national infant immunisation programme. The assessment of the benefits is realised by using an [[Epidemiological_modelling|epidemiological model]]. The effectiveness of the vaccination programme will be quantified as the | The health benefits mean the expected reduction in the annual number of invasive pneumococcal disease in the Finnish population, if the vaccine would be used in the national infant immunisation programme. The assessment of the benefits is realised by using an [[Epidemiological_modelling|epidemiological model]]. The effectiveness of the vaccination programme will be quantified as the | ||
expected improvement in health-associated quality of life. The selection criterion is formulated so that the economically most | expected improvement in health-associated quality of life. The selection criterion is formulated so that the economically most | ||
| − | advantageous product will be chosen (in Finnish: [[Taloudellinen_arviointi|taloudellisen arvioinnin]]). | + | advantageous product will be chosen (in Finnish: [[:op_fi:Taloudellinen_arviointi|taloudellisen arvioinnin]]). |
Revision as of 09:59, 20 June 2014
This page is a assessment.
The page identifier is Op_en6352 |
|---|
| Moderator:Nobody (see all) Click here to sign up. |
|
Give your opinion to the peer rating of the content of this page. |
| Upload data
|
Contents
Question
- How should vaccine products be compared in the national procurement of the pneumococcal conjugate vaccine.
Scope
- We restrict the analysis to vaccination within the infant immunisation programme.
- We specify criteria for comparing pneumococcal conjugate vaccine products (in Finnish: Vertailuperusteet).
- The aim is to prepare selection criteria that lead to choice of the economically most advantageous tender.
- We discuss assumptions underlying the epidemiological model and the cost-effectiveness analysis.
- The preparation of the criteria is based on current knowledge of the efficacy and impact of pneumococcal conjugate vaccines.
- The procurement can only involve a product that has trading license in Finland (see Lääkelain 20a§).
- The procurement must follow the Act on Public Procurement (julkisista hankinnoista annetun lain mukainen).
- The discussion on these pages does not bind the preparation of the procurement.
Answer
Rationale
The rationale has been summarised in the following 3 pages: Vertailuperusteet (in Finnish), Epidemiological modelling ja Taloudellinen arviointi (in Finnish).
Comparison of vaccine products will be based on their price and expected health benefits (in Finnish: vertailuperusteet). The health benefits mean the expected reduction in the annual number of invasive pneumococcal disease in the Finnish population, if the vaccine would be used in the national infant immunisation programme. The assessment of the benefits is realised by using an epidemiological model. The effectiveness of the vaccination programme will be quantified as the expected improvement in health-associated quality of life. The selection criterion is formulated so that the economically most advantageous product will be chosen (in Finnish: taloudellisen arvioinnin).
